MSB Share Price

Open 1.86 Change Price %
High 1.87 1 Day -0.05 -2.70
Low 1.80 1 Week 0.03 1.69
Close 1.80 1 Month -0.19 -9.55
Volume 671782 1 Year 0.29 19.21
52 Week High 3.44
52 Week Low 1.07
MSB Important Levels
Resistance 2 1.86
Resistance 1 1.84
Pivot 1.82
Support 1 1.76
Support 2 1.74
ASX Australia Most Active Stocks
LYC 0.15 7.14%
TLS 3.90 0.78%
TLS 3.90 0.78%
TLS 3.90 0.78%
PCL 0.00 0.00%
PCL 0.00 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
VKA 0.02 100.00%
CAV 0.02 100.00%
CAV 0.02 100.00%
GMD 0.02 100.00%
GMD 0.02 100.00%
RDS 0.02 100.00%
RDS 0.02 100.00%
RDS 0.02 100.00%
AZZ 0.50 78.57%
More..
ASX Australia Top Losers Stocks
NME 0.00 -100.00%
NME 0.00 -100.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
AZS 0.01 -50.00%
AZS 0.01 -50.00%
More..

Mesoblast Ltd (ASX: MSB)

MSB Technical Analysis 1.5
As on 18th Aug 2017 MSB Share Price closed @ 1.80 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.78 & Sell for SHORT-TERM with Stoploss of 1.94 we also expect STOCK to react on Following IMPORTANT LEVELS.
MSB Target for August
1st Target up-side 2.1
2nd Target up-side 2.34
3rd Target up-side 2.59
1st Target down-side 1.4
2nd Target down-side 1.16
3rd Target down-side 0.91
MSB Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.mesoblast.com
MSB Address
MSB
55 Collins Street
Level 39
Melbourne, VIC 3000
Australia
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
MSB Latest News
Mesoblast Limited (MESO) Reports Positive Trial Results of Mesoblast Cell ...   StreetInsider.com   - 16th Aug 17
Form 6-K MESOBLAST LTD For: Aug 18   StreetInsider.com   - 16th Aug 17
Is the Mesoblast limited share price good value?   Motley Fool Australia   - 25th May 17
Is the Mesoblast limited share price about to blast off?   Motley Fool Australia   - 10th Apr 17
Is it too late to buy Mesoblast limited, Challenger Ltd, and CSL Limited?   Motley Fool Australia   - 05th Apr 17
Why the Mesoblast limited share price has been crushed today   Motley Fool Australia   - 27th Mar 17
Durable Three-Year Outcomes In Degenerative Disc Disease After a Single ...   GlobeNewswire (press release)   - 15th Mar 17
Why MesoBLAST limited is rocketing higher on FDA approval   Motley Fool Australia   - 09th Mar 17
Why the Mesoblast limited share price is taking off   Motley Fool Australia   - 13th Jan 17
Here's why beaten down Mesoblast limited is making a comeback   Motley Fool Australia   - 10th Aug 16
Interactive Technical Analysis Chart Mesoblast Ltd ( MSB ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Mesoblast Ltd
MSB Business Profile
Mesoblast Limited, a clinical development company, is engaged in the research and development of its propriety stem cell technologies for use in the treatment of multiple major disease states and other medical conditions. The company’s cell-based core technologies include its Mesenchymal Precursor Cell (MPC) technology platform, which is used to develop products derived from bone marrow and adipose tissue sources; Dental Pulp Stem Cells technology; and expanded Hematopoietic Stem Cells technology. It develops products for intravenous administration to target unmet medical needs in diseases of excessive inflammation and immune dysfunction, including type 2 diabetes, inflammatory joint diseases, and inflammatory lung diseases; MPC treatment therapies for diseases of the spine; adult stem cell-based therapies for the treatment of cardiovascular diseases, including congestive heart failure; and products for treating eye diseases, neurologic diseases, and cord blood expansion. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf (allogeneic) adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPC products in various diseases, including cardiovascular diseases and neurologic conditions. It has operations in Australia, the United States, and Singapore. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.